Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.32 |
| ▸ | SLC2A9 | Q9NRM0 | 2/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970067 | 0.77 | PTPN1 (0.46) | MEN1POLBMAPTKMT2ACYP3A4 | |
| SCHEMBL968657 | 0.67 | PDE9A (0.41) | ABCG2MEN1POLBMAPTKMT2A | |
| SCHEMBL969511 | 0.62 | CYP3A4 (0.50) | MEN1POLBMAPTKMT2ACYP3A4 | |
| SCHEMBL968269 | 0.62 | ABCG2 (0.35) | ABCG2MEN1POLBMAPTKMT2A | |
| SCHEMBL967680 | 0.62 | CYP19A1 (0.41) | ABCG2MAOA | |
| SCHEMBL968424 | 0.61 | ALOX5 (0.45) | — | |
| SCHEMBL970035 | 0.55 | CYP19A1 (0.41) | ABCG2MEN1POLBMAPTKMT2A | |
| SCHEMBL20562001 | 0.55 | PTGS1 (0.32) | — | |
| SCHEMBL11178136 | 0.53 | MAOB (0.53) | MEN1KMT2AMAOA | |
| SCHEMBL31570921 | 0.53 | ABCG2 (1.00) | ABCG2MEN1POLBMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875607-B2 | Neurodegenerative disorders; antiinflammatory agents; antiischemic agents; neuropathic pain; antiepileptic agents; Parkinson's disease; Alzheimer's disease; antidiabetic agents; 3-(6-Hydroxy-2-methyl-3,4,7,8,9,10-hexahydro-7,10-methano-2H -benzo[h]chromen-2-yl)-propionic acid methyl ester | AMPERE LIFE SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | COQ8A, TFAM, CS | ABCG2 518/4885MEN1 3900/4885POLB 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.